A Phase 3 interventional study of PA21 in Hemodialysis Patients With Hyperphosphatemia, sponsored by Kissei Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2018-10-09.
Sponsored by Kissei Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies in Hyperphosphatemia with a site in Japan — 3 open to participants now, 4 under way, 4 of them phase 3. Hyperphosphatemia · Japan.
Among the 41 studies in Hyperphosphatemia with a site in Japan, this one is the 14th largest by enrollment of the 36 interventional ones that give a count, is one of 6 that started in 2013, is one of 23 in phase 3, and was the 20th registered.
173 studies on the registry are indexed under Hyperphosphatemia; 16 are open to participants now.
Browse Hyperphosphatemia studies →3 of the 41 studies in Hyperphosphatemia with a site in Japan are open now. Recruiting first, the newest first:
Taisho Pharmaceutical Co., Ltd. · Sites in Japan
Ages 18+
Taisho Pharmaceutical Co., Ltd. · Sites in Japan
Ages 18+
Taisho Pharmaceutical Co., Ltd. · Sites in Japan
Ages 18+
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 13 Hyperphosphatemia studies recruiting now, 11 (85%) set no upper age limit and 2 (15%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 6 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 161 is above the median of 101 across 143 interventional studies indexed under Hyperphosphatemia.
Median enrollment 117 across the 36 interventional studies, 762 across the 4 observational. Of the 36 that completed or were terminated, 5 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 41 have an industry lead sponsor. The 9 most frequent:
Kissei Pharmaceutical Co., Ltd. is the lead sponsor of 63 studies on the registry; 3 are open to participants now.
Kissei Pharmaceutical Co., Ltd. has 5 studies filed under Hyperphosphatemia — fewer than ten, so there is no comparison to draw.
4 of the studies in Hyperphosphatemia with a site in Japan that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07548840Phase 3Taisho Pharmaceutical Co., Ltd.A Clinical Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis | 2026-11-30 |
| NCT07285291Phase 3Taisho Pharmaceutical Co., Ltd.A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Binders | 2026-12-22 |
| NCT07548853Phase 3Taisho Pharmaceutical Co., Ltd.A Clinical Study of TS-172 in Hyperphosphatemia Patients on Peritoneal Dialysis | 2027-05-31 |
| NCT07285304Phase 3Taisho Pharmaceutical Co., Ltd.A Long-term Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis | 2027-07-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 41 studies in Hyperphosphatemia with a site in Japan, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate the safety and efficacy for 52-week dosing in hemodialysis patients with hyperphosphatemia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: PA21
Incidence of Adverse Events
Time frame: 52 weeks
Serum Phosphorus Concentrations at End of Treatment (Actual Measured Value)
Time frame: 52 weeks
Corrected Serum Calcium Concentrations at End of Treatment (Actual Measured Value)
Time frame: 52 weeks
Serum Intact-PTH Concentrations at End of Treatment (Actual Measured Value)
Time frame: 52 weeks
| Milestone | PA21 |
|---|---|
| Started | 161 |
| Completed | 116 |
| Not completed | 45 |
| Withdrew: Adverse event | 24 |
| Withdrew: Physician decision | 6 |
| Withdrew: Withdrawal by subject | 6 |
| Withdrew: Decrease in serum phosphorus | 4 |
| Withdrew: Decrease in serum calcium | 4 |
| Withdrew: Increase in serum ferritin | 1 |
| Participants | PA21 |
|---|---|
| Incidence of Adverse Events | 152 |
| mg/dL | PA21 |
|---|---|
| Serum Phosphorus Concentrations at End of Treatment (Actual Measured Value) | 5.00 ± 1.17 |
| mg/dL | PA21 |
|---|---|
| Corrected Serum Calcium Concentrations at End of Treatment (Actual Measured Value) | 9.05 ± 0.70 |
| pg/mL | PA21 |
|---|---|
| Serum Intact-PTH Concentrations at End of Treatment (Actual Measured Value) | 251.6 ± 151.4 |
Collected over 52 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PA21 | 3/161 (1.9%) | 29/161 (18%) | 133/161 (82.6%) |
| Event | PA21 |
|---|---|
| Shunt occlusionInjury, poisoning and procedural complications | 4/161 |
| Shunt malfunctionInjury, poisoning and procedural complications | 4/161 |
| Subarachnoid haemorrhageNervous system disorders | 2/161 |
| Angina pectorisCardiac disorders | 2/161 |
| HaematomaVascular disorders | 2/161 |
| Shunt stenosisInjury, poisoning and procedural complications | 2/161 |
| PyelonephritisInfections and infestations | 1/161 |
| Renal cyst infectionInfections and infestations | 1/161 |
| Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/161 |
| Altered state of consciousnessNervous system disorders | 1/161 |
| Event | PA21 |
|---|---|
| NasopharyngitisInfections and infestations | 96/161 |
| DiarrhoeaGastrointestinal disorders | 60/161 |
| ContusionInjury, poisoning and procedural complications | 27/161 |
| Procedural hypotensionInjury, poisoning and procedural complications | 15/161 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 14/161 |
| ExcoriationInjury, poisoning and procedural complications | 14/161 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 12/161 |
| Back painMusculoskeletal and connective tissue disorders | 12/161 |
| GastroenteritisInfections and infestations | 10/161 |
| WoundInjury, poisoning and procedural complications | 10/161 |
Full Analysis Set
| Age, Continuous(years) | PA21 |
|---|---|
| Mean | 58.5 ± 11.1 |
| Sex: Female, Male(Participants) | PA21 |
|---|---|
| Female | 47 |
| Male | 113 |
| Race (NIH/OMB)(Participants) | PA21 |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 160 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Dialysis vintage(months) | PA21 |
|---|---|
| Mean | 85.3 ± 63.2 |
Ran from Mar 2013 to primary completion in Aug 2014, 17 months.
Results were first posted in Oct 2018, 4 years 2 months after primary completion.
Of 21 phase 3 interventional studies under Hyperphosphatemia, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 22. This study's 17 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: PA21
Kissei Pharmaceutical Co., Ltd. →